More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

Abzena, a CDMO, said it has expanded its early- and late-phase analytical capabilities to now include GMP cell-based potency assays at their Cambridge, U.K., and San Diego, CA, development and ...

The companies will work together through the process development, preclinical assessment and initial trials of TCR therapies.

In the ever-evolving cell therapy landscape, the challenge of potency assay development remains critical. At the 4th Cell Therapy Potency Assay Summit, we will unite analytical development ...

they found that it indeed killed the cancer cells with high potency. They also tested the molecule in healthy mice and found no obvious toxic side effects, even though the molecule killed off a ...

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh discusses stem cell therapy, and accessibility to and affordability of such treatment, with Rafael E Carazo Salas ...